Michael Makris, Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on X about a recent paper by Giselle Salmasi et al., commenting:
“Would you give myeloma therapy for Monoclonal Gammopathies of Undetermined Significance (MGUS) ? Probably yes for some cases, after you read this case report in this week’s New England Journal of Medicine (NEJM). The monoclone was linked to anti-PF4 activity with major thrombotic events. Both monoclone and anti-PF4 activity were eliminated post Daratumumab, Bortezomib, Dexamethasone (DVd) therapy. Remember the anti-PF4 is usually not detected on the rapid assays.”
Myeloma Therapy for Monoclonal Gammopathy of Thrombotic Significance published in The New England Journal of Medicine.
Authors: Giselle Salmasi, David L. Murray, Anand Padmanabhan.
